

Table SI. Comparison of cutaneous diffuse large B-cell lymphomas (DLBCLs) according to primary tumour site

Feature	Group A (n=14) n (%) <sup>a</sup>	Group B (n=30) n (%) <sup>b</sup>	p-value
Sex			
Male	9	17	
Female	5	13	
Age, years			
Range	37–81	18–82	
Mean	60.3	57.1	0.289
>60 years	8/14 (57)	15/30 (50)	0.659
Cutaneous involvement			
Localized	13/14 (93)	16/30 (53)	
Extensive	1/14 (7)	14/30 (47)	0.010*
Multiple	5/14 (36)	16/30 (53)	
Single	9/14 (64)	14/30 (47)	0.276
Location of skin lesions			
Leg	6/14 (43)	16/30 (53)	0.517
Non-leg	8/14 (57)	14/30 (47)	
Clinical features of skin lesions			
Nodules	11/14 (79)	25/30 (83)	0.695
Non-nodules such as papules and plaques	4/14 (29)	6/30 (20)	
TNM classification (13)			
T classification			
T1a	3/14 (21)	5/30 (17)	
T1b	6/14 (43)	9/30 (30)	
T2a	0/14 (0)	2/30 (15)	
T2b	2/14 (14)	0/30 (0)	
T2c	2/14 (14)	0/30 (0)	
T3a	1/14 (7)	9/30 (30)	
T3b	0/14 (0)	5/30 (17)	
N classification			
N0	13/14 (93)	6/30 (20)	
N1	0/14 (0)	2/30 (7)	
N2	1/14 (7)	10/30 (33)	
N3	0/14 (0)	12/30 (40)	
M classification			
M0	0/14 (0)	23/30 (77)	
M1	0/14 (0)	7/30 (23)	
Stage			
Low (1–2)	13/14 (93)	8/30 (27)	0.000*
High (3–4)	1/14 (7)	22/30 (73)	
IPI score			
0–2	13/14 (93)	6/30 (20)	
3–5	1/14 (7)	24/30 (80)	0.000*
Serum LDH			
Elevated	4/14 (28)	20/30 (67)	0.025*
B-symptom, positive	2/14 (14)	14/30 (43)	0.049*
Bcl-2 expression, positive	6/9 (67)	18/25 (72)	1.000
Bcl-6 expression, positive	3/9 (33)	12/25 (48)	0.697
MUM-1 expression, positive	6/7 (86)	16/19 (84)	0.588
Treatment			
CTx only	10/14 (71)	20/30 (67)	
CHOP	4/14 (29)	6/30 (20)	
R-CHOP	6/14 (43)	13/30 (43)	
ESHAP	0/14 (0)	5/30 (15)	
CTx with RTx	1/14 (7)	7/30 (23)	
CHOP	1/14 (7)	3/30 (10)	
R-CHOP	0/14 (0)	5/30 (15)	
ESHAP	0/14 (0)	3/30 (10)	
CTx with ASCT	0/14 (0)	3/30 (10)	

<sup>a</sup>Group A: DLBCL, leg type. <sup>b</sup>Group B: secondary cutaneous DLBCL. \*Statistically significant. \*\*ISCL-EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides and Sézary syndrome. T1a: a solitary lesion <5 cm in diameter; T1b: a solitary lesion >5 cm in diameter; T2a: all-disease-encompassing in a <15-cm-diameter circular area; T2b: all-disease-encompassing in a >15- and <30-cm-diameter circular area; T2c: all-disease-encompassing in a >30-cm-diameter circular area; T3a: multiple lesions involving two non-contiguous body regions; T3b: multiple lesions involving ≥3 body regions; N0: no clinical or pathologic lymph node involvement; N1: involvement of 1 peripheral lymph node region + that drains an area of current or prior skin involvement; N2: involvement of 2 or more peripheral lymph node regions + or involvement of any lymph node region that does not drain an area of current or prior skin involvement; N3: involvement of central lymph nodes; M0: no evidence of extracutaneous non-lymph node disease; M1: extracutaneous non-lymph node disease present. ASCT: autologous bone marrow stem cell transplant; Ctx: chemotherapy; IPI: International Prognostic Index; LDH: lactic dehydrogenase; RTx: radiation therapy; TNM classification: tumour-node-metastasis classification.